Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Athira Pharma (ATHA)
NASDAQ:ATHA
Holding ATHA?
Track your performance easily
ATHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $4.30
Previous Close$0.67
Volume71.75K
Average Volume (3M)5.22M
Market Cap
$25.52M
Enterprise Value-$41.63M
Total Cash (Recent Filing)$68.86M
Total Debt (Recent Filing)$1.31M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Mar 20, 2025EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.85
Shares Outstanding38,669,073
10 Day Avg. Volume3,360,162
30 Day Avg. Volume5,216,305
Standard Deviation0.28
R-Squared0.24
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$0.58Price Target Upside-12.12% Downside
Rating ConsensusHold
Number of Analyst Covering5
Athira Pharma News
PremiumMarket News
3 Penny Stocks to Watch Now, 11/5/24
PremiumCompany Announcements
Athira Pharma Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsClinical and preclinical NfL biomarker data from the program support a role for HGF modulation as a target for neurodegeneration.
Drug DevelopmentThe company remains focused on advancing next-gen oral HGF/MET modulator ATH-1105.
Financial StrategyThe company has initiated a strategic review process to explore strategic alternatives, including the potential to secure a strategic partnership for ATH-1105.
Bears Say
Clinical Trial ResultsThe Phase 2/3 LIFT-AD trial did not meet its primary or key secondary endpoints.
Financial StrategyThe company also announced cost-cutting measures, including a workforce reduction of 70%, which extends projected cash runway through 1Q26.
Stock PerformanceThe stock traded off ~75% after market and at this level is trading at ~35% of cash at the end of August.
---
Ownership Overview
24.08% Insiders
6.19% Mutual Funds
25.60% Other Institutional Investors
35.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATHA FAQ
What was Athira Pharma’s price range in the past 12 months?
Athira Pharma lowest stock price was $0.41 and its highest was $4.30 in the past 12 months.
What is Athira Pharma’s market cap?
Currently, no data Available
When is Athira Pharma’s upcoming earnings report date?
Athira Pharma’s upcoming earnings report date is Mar 20, 2025 which is in 122 days.
How were Athira Pharma’s earnings last quarter?
Athira Pharma released its earnings results on Nov 07, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.702 by -$0.048.
Is Athira Pharma overvalued?
According to Wall Street analysts Athira Pharma’s price is currently Overvalued.
Does Athira Pharma pay dividends?
Athira Pharma does not currently pay dividends.
What is Athira Pharma’s EPS estimate?
Athira Pharma’s EPS estimate is -$0.45.
How many shares outstanding does Athira Pharma have?
Athira Pharma has 38,669,070 shares outstanding.
What happened to Athira Pharma’s price movement after its last earnings report?
Athira Pharma reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.702. Following the earnings report the stock price went down -12%.
Which hedge fund is a major shareholder of Athira Pharma?
Among the largest hedge funds holding Athira Pharma’s share is Perceptive Advisors LLC. It holds Athira Pharma’s shares valued at 2M.
---
Athira Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.58 (-12.12% Downside)
$0.58 (-12.12% Downside)
Insider Transactions
Sold Shares
Worth $7.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.86%
12-Months-Change
Fundamentals
Return on Equity
-102.87%
Trailing 12-Months
Asset Growth
-53.30%
Trailing 12-Months
Company Description
Athira Pharma
Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.
---
ATHA Stock 12 Month Forecast
Average Price Target
$0.58
▼(-12.12% Downside)
Technical Analysis
SELLAS Life Sciences Group
―
Alzamend Neuro
―
Anavex Life Sciences
―
Bioxcel Therapeutics
―
---